Table 2.
Incremental effectiveness and costs of adjuvant S-1 therapy (discount rate: 3% for both effectiveness and costs)
| Period | S-1 therapy | Surgery alone | Incremental effectiveness and costs (95% CI) |
|---|---|---|---|
| Effectiveness | |||
| |
QALYs |
|
|
| 5-year observation |
3.11 |
2.84 |
0.27 (0.11 – 0.42) |
| 10-year follow-up |
5.08 |
4.45 |
0.64 (0.28 – 0.99) |
| Over lifetime |
8.65 |
7.41 |
1.24 (0.48 – 1.96) |
| |
Costs ($) |
|
|
| 5-year observation |
10,802 |
7,408 |
3,389 (2,616 – 4,174) |
| 10-year follow-up |
12,110 |
8,523 |
3,585 (2,750 – 4,411) |
| Over lifetime |
13,057 |
9,346 |
3,722 (2,911 – 4,512) |
| Incremental cost-effectiveness ratio | |||
| |
Cost ($) per QALY gained |
(95% CI) |
|
| 5-year observation |
12,716 |
(6,428 – 34,018) |
|
| 10-year follow-up |
5,608 |
(2,855 – 14,569) |
|
| Over lifetime | 3,016 | (1,441 – 8,840) | |
CI = confidence interval; QALYs = quality-adjusted life-years.